Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 19, 2017
Pharmacy Choice - News - Generic Drugs - September 19, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/20/17 - BRIEF: Teva launches generic testosterone boost treatment [Globes, Tel Aviv, Israel]
Aug. 20 Teva Pharmaceutical Industries Ltd. has announced the launch of generic Axiron topical solution CIII, 30 mg/1. 5 mL, in the US. With nearly 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending fir
8/20/17 - Mylan finalizes settlement over Medicaid payments for EpiPen
PITTSBURGH Generic drug giant Mylan announced Thursday it has finalized its settlement with the U.S. Department of Justice for overcharging Medicaid for the EpiPen. The settlement amount is $465 million, unchanged from when Mylan announced a preliminary deal in October that was criticized by lawmakers and others as not being harsh enough.
8/19/17 - Government seeks caps on drug trade margins [Tehran Times (Iran)]
The government plans to cap trade margins to make drugs cheaper, replace brand names with salt names for generic drugs, clamp down on unfair marketing practices and boost local manufacturing to reduce dependence on imports, according to government`s draft national pharmaceutical policy. The draft, prepared by the pharmaceuticals department, also su
8/19/17 - Gwq Generic Tender (tacrolimus-aliud). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement regarding products with the active ingredient tacrolimus of the manufacturer ALIUD PHARMA GmbH. Time-limit for receipt of tenders or requests to participate: Date 15/08/2017 Local time 1000 IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected
8/19/17 - Gwq Generic Tender (tacrolimus-astellas). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement regarding products with the active ingredient Tacrolimus from the manufacturer Astellas Pharma GmbH. Time limit for receipt of tenders or requests to participate: Date: 15/08/2017 Local time: 10:00 Major organization: GWQ SERVICEPLUS AG Address: Tersteegenstr. 28 Dsseldorf 40476
8/19/17 - Gwq Generic Tender (tacrolimus-heumann). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement agreement for products with the active ingredient Tacrolimus from the manufacturer Heumann Pharma GmbH& Co. Generika KG. Time limit for receipt of tenders or requests to participate: Date: 15/08/2017 Local time: 10:00 Major organization: GWQ SERVICEPLUS AG Address: Tersteegenstr
8/19/17 - Gwq Generic Tender (tacrolimus-stada). [TendersInfo (India)]
Contract notice: Gwq generic tender. Conclusion of a generic agreement agreement for products with the active substance tacrolimus of the manufacturer STADApharm GmbH. Time limit for receipt of tenders or requests to participate: Date: 15/08/2017 Local time: 10:00 Major organization: GWQ SERVICEPLUS AG Address: Tersteegenstr. 28 Dsseldorf 40474 Ger
8/18/17 - Biocons biosimilars withdrawn in EU [Algeria Press Service]
Corrective and preventive actions will be completed by the end of this quarter and Biocon hopes to ask for a re-inspection once they are complete, followed by a refiling. Biocon and partner Mylan became the first companies to file a biosimilar of Roches big-selling breast cancer drug Herceptin in the EU last summer, shortly after filing a biosimila
8/18/17 - Clinical Trial Supplies Market is Anticipate To Accelerate Growth Owing To Increasing Complexities, Rising Number Of Biologics And Biosimilar Drugs Till 2025: Grand View Research, Inc.
"Grand View Research, Inc.- Market Research And Consulting." According to report published by Grand View Research, Global Clinical Trial Supplies Market size was valued at USD 1.7 billion in 2016 and Advancement in supply chain management technology is also expected to be the major driver for growth of the supplies market. The Global Clinical Trial
8/18/17 - Company Spotlight: ANI Pharmaceuticals
WASHINGTON- In today's Spotlight column, the company we are featuring is ANI Pharmaceuticals Inc.. ANI Pharma develops, manufactures and markets branded and generic prescription pharmaceuticals, and also provides contract manufacturing services to select clients. ANI Pharmaceuticals also has a well-stocked pipeline- with 71 generic products and 5..
8/18/17 - Daily Mail, London, Market Report column [Daily Mail, London]
The FTSE 250 firm and its partner Vectura were savaged in May after failing to gain US regulatory approval for a generic version of rival GlaxoSmithKline's asthma drug Advair. As a result, Hikma downgraded full-year revenue estimates for its generics arm to 481.2 m from 520 m in May itself a downgrade from a 621 m forecast in April. Star fu
8/18/17 - Mishcon De Reya Added Onto the Speaker Line-Up for 8th Annual Biosimilars Industry Summit
Mishcon de Reya to present on the role of competition and IP law for Biosimilars at 8th annual industry meeting.
8/18/17 - Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability for Underpaying EpiPen Rebates
Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department announced today. Mylan Inc. and Mylan Specialty L.P. are both wholly ow
8/18/17 - Supernus Defeats Second Generic Challenger to Oxtellar XR
Release date- 17082017- ROCKVILLE, Md.- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced, following a four-day bench trial, that the United States District Court for the District of New Jersey ruled that TWi...
8/18/17 - Teva Announces Exclusive Launch of Generic Axiron in the United States
Teva Pharmaceutical Industries Ltd., today announced the launch of generic Axiron 1 topical solution CIII, 30 mg/1. 5 mL, in the U.S.. We are pleased with the result in the district court, which has helped Teva add yet another product to our industry-leading generic portfolio, providing savings to our customers and to patients, said Andy B
8/18/17 - Vectura Group plc - Hikma Interim Results statement on its ANDA for generic Advair Diskus
Release date- 17082017- Chippenham, UK- Vectura Group plc, an industry-leading device and formulation business for inhaled airways products, today confirms the statement made by its partner Hikma Pharmaceuticals PLC in its interim results statement in respect of its abbreviated new drug application filing for a US generic version of Advair Diskus:'
8/17/17 - After a slow start, Novartis finally gains market traction with heart drug Entresto [Arab News (Saudi Arabia)]
The market was dominated by generic drugs, so the pricey new entry didnt sit well with pharmacy benefits managers and insurersdespite ringing endorsements from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America, all of which recommended that physicians switch their patients to Entresto.
8/17/17 - EpiPen maker finalizes settlement for government overcharges
EpiPen maker Mylan has finalized a $465 million government agreement settling allegations it overbilled Medicaid for its emergency allergy injectors for a decade charges brought after rival Sanofi filed a whistleblower lawsuit and tipped off the government. On Thursday, the Department of Justice disclosed that its EpiPen case began when...
8/17/17 - Julphar reports first six months earnings [Arab Finance (Egypt)]
ArabFinance: Julphar, the largest generic pharmaceutical manufacturer in Middle East and North Africa, announced sales revenue of AED 639 million in the first semester of the year 2017. Dandasha has been launched during Q1. 17 in the UAE to treat erectile dysfunction in adult men and by Q2, it has become a leader in its segment. Furthermore the
8/17/17 - Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability
BOSTON The U.S. Attorney's Office announced today that pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve allegations that they violated the False Claims Act by knowingly misclassifying EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid.
8/17/17 - Mylan Agrees to Pay $465 Million to Resolve False Claims Act Liability for Underpaying EpiPen Rebates
Pharmaceutical companies Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department announced today. Mylan Inc. and Mylan Specialty L.P. are both wholly ow
8/17/17 - Mylan finalizes $465M settlement over EpiPen billing lawsuit
The Justice Department alleged Mylan violated the False Claims Act by knowingly listing the EpiPen as a generic drug, which is subject to lower rebates under federal law, despite the fact there is no equivalent competitor to lower the price. The Justice Department had filed a civil lawsuit against Mylan, which was resolved by virtue of Thursday's s
8/17/17 - Mylan Launches Three Generic Antiretrovial Medicines for HIV in Canada [All Iraq News Agency (AIN)]
Mylan Pharmaceuticals ULC, a subsidiary of Mylan N.V., a leading global pharmaceutical company, announced the launch in Canada of three generic products indicated in the treatment of HIV for certain patients. Mylan received final approval from Health Canada for this product and for Mylan-Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate 600 mg,
8/17/17 - North America Drug Delivery Market 2017-2024 - Rising Demand for Biosimilars and Generic Drugs
The "North America Drug Delivery Market- Trends and Forecast to 2024" report has been added to Research and Markets' offering. The North America Drug Delivery Market is expected to reach USD 823.55 billion by 2024, at a CAGR of 6.4% during the forecast period of 2017 to 2024.. North America Drug Delivery Market is segmented based on product type,
8/17/17 - Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog II Cream
Release date- 16082017- DUBLIN- Perrigo Company plc today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Mycolog II Cream. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Aff
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415